CDK4/6 inhibitors in breast cancer: spotting the difference

Article Oncology

Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells

Ryohei Ogata et al.

Summary: Acquired resistance to PAL or ABE in breast cancer cells confers cross-resistance to the other CDK4/6 inhibitor but not to chemotherapeutic agents. Down-regulation of basal RB expression and normalized RB phosphorylation reduced by CDK4/6 inhibitors may be responsible for the attenuated anti-cell growth effects of the inhibitors.

BREAST CANCER (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

Binghe Xu et al.

Summary: Combination therapy of dalpiciclib and fulvestrant significantly prolongs progression-free survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer, with neutropenia and leukopenia being the most common grade 3 or 4 adverse events. Serious adverse events rate is relatively low and supports dalpiciclib plus fulvestrant as a new treatment option for pretreated patients.

NATURE MEDICINE (2021)

Add to Collection

Article Oncology

Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

Aleix Prat et al.

Summary: This study aimed to evaluate the prognostic and predictive value of intrinsic subtypes in hormone receptor-positive, HER2-negative advanced breast cancer treated with endocrine therapy and ribociclib. The results showed that all intrinsic subtypes except basal-like benefited from ribociclib treatment with consistent PFS improvement.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology